Partial
Needs Correction
Patient Risk:
Moderate
Summary
The response’s mg↔mL conversion logic is not fully supported as stated. The label excerpt confirms oral suspension is “6 mg per mL” (after constitution), but does not explicitly define a conversion formula or “final concentration is 12 mg per mL.”
Category Scores
Accurate Statements
If a clinician orders a dose of X mg, then the volume to measure is mL = (mg dose) / 12.
Not supported with the provided label excerpt because the excerpt specifies oral suspension concentration as 6 mg/mL after constitution, not 12 mg/mL.
Unsupported Statements
Tamiflu oral suspension is supplied so the final concentration is 12 mg per mL (12 mg/mL).
Label excerpt states TAMIFLU for oral suspension is preferred formulation (6 mg per mL) for patients who cannot swallow capsules; no 12 mg/mL concentration is provided.
The dose in mg equals the dose in mL multiplied by 12.
Label excerpt provides concentration of 6 mg per mL after constitution, not 12 mg per mL; therefore the mg↔mL multiplier of 12 is not supported.
If a clinician orders a dose of X mg, then the volume to measure is mL = (mg dose) / 12.
Label excerpt supports oral suspension concentration of 6 mg per mL (after constitution), not 12 mg per mL; thus the division by 12 is not supported.
Contradictions
Low
AI Statement
Tamiflu oral suspension is supplied so the final concentration is 12 mg per mL (12 mg/mL).
Label Reference
2.1 Dosage and Administration Overview: “TAMIFLU for oral suspension (supplied as a powder). This is the preferred formulation (6 mg per mL)…”
Important Omissions
The label excerpt specifies the oral suspension concentration as 6 mg per mL after constitution (and notes it is supplied as a powder). The response omits the “after constitution” context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Using an incorrect concentration multiplier (12 instead of the label’s 6 mg/mL) would change calculated volume measurements. The label excerpt explicitly states 6 mg/mL, so the response’s dosing-conversion statements are likely inaccurate.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Correction
Primary Issue
Incorrect oral suspension concentration stated as 12 mg/mL instead of label excerpt’s 6 mg/mL (after constitution).
Suggested Improvement
Re-state the oral suspension concentration per the label excerpt as 6 mg/mL and only provide a conversion formula consistent with that concentration (and clarify it is after constitution).